检索结果-南通市图书馆

World Journal of Gastroenterology 2007年第8期13卷 1175-1181页

作者： Ji Yeon Baek Wonhee Hur Jin Sang Wang Si Hyun Bae seung kew yoon Department of Internal Medicine College of Medicine The Catholic University of Korea 505 Banpo-dong Seocho-gu 137-701 Seoul Korea WHO Collaborating Center for Reference and Research on Viral Hepatitis The Catholic University of Korea 505 Banpo-dong Seocho-gu 137-701 Seoul Korea

AIM: To investigate the growth inhibitory mechanism of NS-398, a selective cyclooxygenase-2 (COX-2) inhibitor, in two hepatocellular carcinoma (HCC) cell lines (HepG2 and Huh7). METHODS: HepG2 and Huh7 cells were treated with NS-398. Its effects on cell viability, cell proliferation, cell cycles, and gene expression were respectively evaluated by water-soluble tetrazolium salt (WST-1) assay, 4’-6-diamidino-2-phenylindole (DAPI) staining, flow cytometer analysis, and Western blotting, with dimethyl sulfoxide (DMSO) as positive control. RESULTS: NS-398 showed dose- and time-dependent growth-inhibitory effects on the two cell lines. Proliferating cell nuclear antigen (PCNA) expressions in HepG2 and Huh7 cells, particularly in Huh7 cells were inhibited in a time- and dose-independent manner. NS-398 caused cell cycle arrest in the G1 phase with cell accumulation in the sub-G1 phase in HepG2 and Huh7 cell lines. No evidence of apoptosis was observed in two cell lines. CONCLUSION: NS-398 reduces cell proliferation by inducing cell cycle arrest in HepG2 and Huh7 cell lines, and COX-2 inhibitors may have potent chemoprevention effects on human hepatocellular carcinoma.

关键词： Selective cyclooxygenase 2 inhibitor Cell growth Cell cycle Hepatocellular carcinoma cells

Update on hepatitis B virus infection

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2014年第37期20卷 13293-13305页

作者： Chan Ran You Sung Won Lee Jeong Won Jang seung kew yoon Division of Hepatology Department of Internal MedicineCollege of MedicineSeoul St. Mary’s HospitalThe Catholic University of Korea

Chronic infection with hepatitis B virus (HBV) leads to the development of hepatocellular carcinoma and/or chronic liver failure. Despite extensive research, the immunopathogenesis is not completely understood. Viral persistence and clinical outcomes following HBV infection depend on viral factors and host factors; including genetic factors that determine a host’s immune mechanisms. The primary goal of chronic hepatitis B (CHB) treatment is to eradicate HBV or to at least maintain suppression of HBV replication. Despite recent advances in anti-viral agents for chronic HBV infection, complete eradication of the virus has been difficult to achieve. Agents for the treatment of CHB are divided mainly into two groups: immunomodulating agents and antiviral nucleos(t)ide analogues (NAs). Although NAs are safe, effective and easily administered orally, their long-term use poses the risk of drug resistance. Currently, international evidence-based guidelines have been developed to support physicians in managing CHB patients. However, treatment of patients with drug resistance is still challenging, as only a few classes of anti-HBV drugs are available and cross-resistance between drugs can occur. In addition, as the currently available genotypic test for detection of drug resistance still has limitations in identifying the different substitutions present in the same viral genome, the development of a new virologic test to overcome this limitation is necessary. Among the predictive factors associated with response to pegylated interferon (PEG-IFN) therapy, hepatitis B surface antigen quantification is considered to be a surrogate marker for monitoring response to PEG-IFN. Current practice guidelines stress the importance of profound and durable HBV viral suppression in the treatment of CHB patients. To this end, it is essential to choose a potent antiviral drug with a low risk of resistance for initial treatment of CHB to achieve sustained virological response. This rev

关键词： Hepatitis B virus Chronic hepatitis B Nucleos(t)ide analogue Pegylated interferon Antiviral therapy

A newly developed subcutaneous nodule 15 years after liver transplantation

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary Surgery and Nutrition 2021年第3期10卷 430-432页

作者： Soon Kyu Lee Pil Soo Sung seung kew yoon Department of Internal Medicine College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea

A 79-year-old man,who had undergone liver transplantation(LT)15 years ago due to hepatocellular carcinoma(HCC)related to chronic hepatitis B,was referred for a newly developed 2 cm-sized mass on his left cheek(Figure 1A).Alpha-fetoprotein had been within normal range since LT,and the patient had been on 1 mg/day *** emission tomography-computed tomography documented a focal 18F-fluorodeoxyglucose uptake in skin lesion(Figure 1B).

关键词： liver Figure fetoprotein

Family history influences the early onset of hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2012年第21期18卷 2661-2667页

作者： Chung-Hwa Park seung-Hee Jeong Hyeon-Woo Yim Jin Dong Kim Si Hyun Bae Jong Young Choi seung kew yoon Department of Internal Medicine The Catholic University of KoreaSeoul 137-701 South Korea Department of Preventive Medicine College of Medicine The Catholic University of KoreaSeoul 137-701 South Korea Clinical Research Coordinating Center of Catholic Medical Center The Catholic University of KoreaSeoul 137-701 South Korea

AIM: To evaluate the relationship between a positive family history of primary liver cancer and hepatocellular carcinoma (HCC) development in Korean HCC patients. METHODS: We studied a total of 2242 patients diagnosed with HCC between January 1990 and July 2008, whose family history of primary liver cancer was clearly described in the medical *** family history of HCC and 2077 (92.6%) did not. The male to female ratio was 3.6:1, and the major causes of HCC were chronic hepatitis B virus (HBV) infection in 75.1%, chronic hepatitis C virus infection in 13.2% and alcohol in 3.1%. The median ages at diag- nosis in the positiveand negative-history groups were 52 years (range: 29-79 years) and 57 years (range: 18-89 years), respectively (P < 0.0001). Furthermore, among 1713 HCC patients with HBV infection, the number of patients under 45 years of age out of 136 patients with positive family history was 26 (19.1%), whereas those out of 1577 patients with negative family history was 197 (12.5%), suggesting that a positive family history may be associated with earlier development of HCC in the Korean population (P = 0.0028). CONCLUSION: More intensive surveillance maybe recommended to those with a positive family history of HCC for earlier diagnosis and proper management especially when HBV infection is present.

关键词： Liver cancer Hepatocellular carcinoma Family history Epidemiology

Molecular mechanism of hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatoma Research 2018年第8期4卷 31-39页

作者： seung kew yoon Division of Hepato-Gastroenterology Department of Internal MedicineCollege of MedicineThe Catholic University of Korea The Catholic University Liver Research Center&WHO Collaborating Center of Viral Hepatitis SeoulSouth Korea

Development of hepatocellular carcinoma (HCC) is very complex and occurs through a multistep biological process of malignant transformation of normal hepatocytes in which various factors, including genetic and epigenetic alterations, regulation of oxidative stress, inflammation, and immunity are involved. To date, numerous studies have described the molecular pathogenesis of HCC, but the precise molecular mechanisms of HCC development remain unclear. Emerging single-cell transcriptome analysis technology is a powerful tool for defining sub-populations within heterogeneous bulk tumor tissue and allows molecular characterization of each cell. This breakthrough method can unveil the molecular mechanisms of HCC. In this article, I discuss recent advances in the molecular pathogenesis of HCC through this newly emerging concept of single-cell analysis.

关键词： Hepatocellular carcinoma molecular mechanism pathogenesis characterization

Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第8期22卷 2592-2600页

作者： Myong Ki Baeg seung kew yoon Sun-Hye Ko Yong-Sun Noh In-Seok Lee Myung-Gyu Choi Department of Internal Medicine The Catholic University of Korea College of Medicine

AIM: To determine whether Helicobacter pylori (H. pylori) infection confers a higher risk of Nonalcoholic fatty liver disease (NAFLD).METHODS: Healthy people who underwent health screening were analyzed retrospectively. Inclusion criteria were age ≥ 20 years, history of H. pylori infection, and recorded insulin level. Participants were classified as H. pylori positive or negative according to 13C urea breath tests. NAFLD was defined using the hepatic steatosis index (HSI) and NAFLD liver fat score (NAFLD-LFS). Those with an HSI > 36 or NAFLD-LFS > -0.640 were considered to have NAFLD. Multivariable logistic regression was performed to identify risk factors for ***: Three thousand six hundred and sixty-three people were analyzed and 1636 (44.7%) were H. pylori positive. H. pylori infection was associated with older age, male gender, hypertension, higher body mass index, and a dyslipidemic profile. HSI differed significantly between H. pylori positive and negative subjects (median 33.2, interquartile range (IQR) 30.0-36.2 for H. pylori-positive vs median 32.6, IQR 29.8-36.0 for negative participants, P = 0.005), but NAFLD-LSF did not [median -1.7, IQR -2.4 - -0.7 vs median -1.8, IQR -2.4-(-0.7), respectively, P = 0.122]. The percentage of people with NAFLD did not differ between infected and uninfected groups: HIS, 26.9% vs 27.1%, P = 0.173; NAFLD-LFS, 23.5% vs 23.1%, P = 0.778. H. pylori infection was not a risk factor, but C-reactive protein concentration and smoking were significant risk factors for ***: H. pylori infection is not a risk factor for NAFLD as indicated by HSI or NAFLD-LFS. Prospective, large-scale studies involving liver biopsies should be considered.

关键词： Helicobacter pylori Nonalcoholic fatty liver disease Hepatic steatosis index Nonalcoholic fatty liver disease liver fat score Urea breath test

Epirubicin,Cisplatin,5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2014年第1期20卷 235-241页

作者： Ji Eun Lee Si Hyun Bae Jong Young Choi seung kew yoon Young Kyoung You Myung Ah Lee Division of Medical Oncology Hepato-Biliary-Pancreatic Cancer CenterCancer Research Institute Seoul St. Mary’s HospitalCollege of MedicineThe Catholic University of KoreaSeoul 137-040South Korea Department of Internal Medicine Hepato-Biliary-Pancreatic Cancer CenterCancer Research InstituteSeoul St. Mary’s HospitalCollege of MedicineThe Catholic University of KoreaSeoul 137-040South Korea Division of Hepatology Hepato-Biliary-Pancreatic Cancer CenterCancer Research Institute Seoul St. Mary’s HospitalCollege of MedicineThe Catholic University of KoreaSeoul 137-040South Korea Department of Surgery Hepato-Biliary-Pancreatic Cancer CenterCancer Research InstituteSeoul St. Mary’s HospitalCollege of MedicineThe Catholic University of KoreaSeoul 137-040South Korea

AIM: To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC).

关键词： Hepatocellular carcinoma Sorafenib Epirubicin Cisplatin 5-FU

Heterogenous responses to nivolumab in a single metastatic nodule in hepatocellular carcinoma: role of salvage surgery

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary Surgery and Nutrition 2019年第5期8卷 569-571页

作者： Hyun Yang Pil Soo Sung Jaejun Lee seung kew yoon Eun Sun Jung Cheon-Soo Park Si Hyun Bae The Catholic University Liver Research Center College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea Department of Internal medicine College of MedicineEunpyeong St.Mary’s HospitalThe Catholic University of KoreaSeoulRepublic of Korea Department of Internal Medicine College of MedicineSeoul St.Mary’s HospitalThe Catholic University of KoreaSeoulRepublic of Korea Department of Hospital Pathology College of MedicineEunpyeong St.Mary’s HospitalThe Catholic University of KoreaSeoulRepublic of Korea Department of Surgery College of MedicineEunpyeong St.Mary’s HospitalThe Catholic University of KoreaSeoulRepublic of Korea

A recent report demonstrated immune heterogeneityof hepatocellular carcinoma(HCC)(1).The objectiveresponse rates of sorafenib-treated global and Asian patientsby nivolumab,the monoclonal antibody to programmedcell dea... 详细信息

关键词： hepatocellular nivolumab surgery

Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2008年第11期14卷 1781-1784页

作者： Soon Woo Nam Si Hyun Bae seung Woo Lee Yeon Soo Kim Sang Bum Kang Jong Young Choi Se Hyun Cho seung kew yoon Joon-Yeol Han Jin Mo Yang Young Suk Lee Division of Gastroenterology and Hepatology Department ofInternal medicineMedical College of the Catholic University ofKoreaDaejeon St.Mary's Hospital#62 Daeheung-dongChung-guDaejeonRepublic of Korea

AIM： To evaluate the efficacy of short-term overlap lamivudine therapy with adefovir in patients with lamivudine-resistant and naive chronic hepatitis B, we compared patients receiving overlap therapy with those receiving adefovir alone. METHODS： Eighty patients who had received lamivudine treatment for various periods and had a lamivudineo resistant liver function abnormality were enrolled. Forty of these patients received adefovir treatment combined with lamivudine treatment for ≥ 2 mo, while the other 40 received adefovir alone. We assessed the levels of hepatitis B virus （HBV） DNA at 0, 12 and 48 wk and serum alanine aminotransferase （ALT） levels after 0, 12, 24 and 48 wk of adefovir treatment in each group. RESULTS： We found serum ALT became normalized in 72 （87.5%） of the 80 patients, and HBV DNA decreased by ≥ 2 Ioglo copies/mL in 60 （75%） of the 80 patients at the end of a 48-wk treatment. HBV DNA levels were not significantly different between the groups. The improvements in serum ALT were also not significantly different between the two groups. CONCLUSION： These findings suggest short-term overlap lamivudine treatment results in no better virological and biological outcomes than non-overlap adefovir monotherapy.

关键词： Adefovir dipivoxil Chronic hepatitis B Hepatitis B virus DNA Overlap

Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma:Analysis of prognostic factors

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2008年第37期14卷 5717-5722页

作者： Jong-Bum Kwon Khun Park Young-Du Kim Jong-Hee Seo Seok-Whan Moon Deog-Gon Cho Yong-Whan Kim Dong-Goo Kim seung-kew yoon Hyeon-Woo Lim Department of Thoracic and Cardiovascular Surgery the Catholic University of KoreaSeoul 137-701 Korea Department of Surgery the Catholic University of KoreaSeoul 137-701 Korea Department of Internal Medicine the Catholic University of KoreaSeoul 137-701 Korea Department of Preventive Medicine the Catholic University of KoreaSeoul 137-701 Korea

AIM： To review the surgical outcomes in terms of the surgical indications and relevant prognostic factors. METHODS： Sixteen patients underwent therapeutic lung surgery between March 1999 and May 2006. The observation period was terminated on May 31, 2007. The surgical outcomes and the clinicopathological factors were compared. RESULTS： There was no mortality or major morbidity encountered in this study. The mean follow-up period after metastasectomy was 26.7 ＋ 28.2 （range： 1-99 mo）, and the median survival time was 20 mo. The 1- and 5-year survival rates were 56% and 26%, respectively. At the end of the follow-up, 1 patient died from hepatic failure without recurrence, 6 died from hepatic failure with a recurrent hepatocellular carcinoma （HCC）, and 4 died from recurrent HCC with cachexia. Among several clinical factors, Kaplan Meier analysis revealed as a treatment for the that liver transplantation primary lesion, grade of cell differentiation, and negative evidence HBV infection were independent predictive factors. On Cox＇s proportional hazard model, there were no significant factors affecting survival after pulmonary metastasectomy in patients with HCC. CONCLUSION： A metastasectomy should be performed before other treatments in selected patients, Although not significant, patients with liver transplantation of a primary HCC survived longer, Liver transplantation might be the most beneficial modality that can offer patients better survival, A multi- institutional and collaborative study would be needed for identifying clinical prognostic factors predicting survival in patients with HCC and lung metastasis.

关键词： Hepatocellular carcinoma Pulmonary metastasis Metastasectomy Liver transplantation Thoracoscopy